The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy

PURPOSE: The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted to evaluate the efficacy and safety of anlot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tian, Lin, Feng, Huang, Yujing, Qian, Guowei, Yu, Wenxi, Hu, Haiyan, Ji, Tong, Tang, Lina, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547547/
https://www.ncbi.nlm.nih.gov/pubmed/36217441
http://dx.doi.org/10.2147/CMAR.S378264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547547/
https://www.ncbi.nlm.nih.gov/pubmed/36217441
http://dx.doi.org/10.2147/CMAR.S378264

Ejemplares similares